Mitochondrial DNA heteroplasmy in disease and targeted nuclease-based therapeutic approaches

Area of Science:

• Genetics
• Molecular Biology
• Biochemistry

Background:

• Mitochondrial DNA (mtDNA) mutations are often heteroplasmic, with disease manifesting above a certain pathogenic load.
• Germline mtDNA segregation causes significant intergenerational heteroplasmy variation.
• Mitochondrial diseases arising from pathogenic mtDNA mutations currently lack effective cures.

Purpose of the Study:

• To explore gene therapy as a strategy for correcting pathogenic mtDNA heteroplasmy.
• To investigate the potential of engineered nucleases for shifting heteroplasmy towards wild-type mtDNA.
• To evaluate therapeutic approaches for mitochondrial diseases linked to mtDNA mutations.

Main Methods:

• Utilizing mitochondrially targeted engineered nucleases (mitoTALENs and mitoZFNs).
• In vitro studies using human cells with patient-derived pathogenic mtDNA mutations.
• In vivo studies in a mouse model of a pathogenic mtDNA point mutation.

Main Results:

• Demonstrated the use of mitoTALENs and mitoZFNs in vitro to target pathogenic mtDNA.
• Successfully applied these gene therapy tools in vivo in a mouse model.
• Showcased the potential for shifting mtDNA heteroplasmy towards wild-type levels.

Conclusions:

• Engineered nucleases represent a promising gene therapy approach for managing mtDNA heteroplasmy.
• This strategy could offer a therapeutic option for patients with mitochondrial diseases.
• These tools may complement other strategies for preventing mother-to-child transmission of pathogenic mtDNA.